A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis

Key facts

Sponsor

Ipsen

Principal Investigator

Ipsen Medical Director

Ipsen

Intervention

Elafibranor(drug)

Enrollment

350 enrolled

Eligibility

18-75 years · All sexes

Timeline

2026 – 2031

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Primary sclerosing cholangitis

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE2NCT07567274
  DMSO Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Post-COVID-19 Vaccine Injury
  Leading Edge Clinic
• RECRUITINGPHASE1NCT07229911
  A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)
  Takeda
• RECRUITINGPHASE2NCT06699121
  A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC
  LISCure Biosciences
• RECRUITINGPHASE2NCT06905054
  Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
  Mayo Clinic
• RECRUITINGNANCT06865924
  Colangioids to Define the Genetic Factors Involved in Atypical Primary Sclerosing Cholangitis
  Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
• RECRUITINGNCT06297993
  Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)
  PSC Partners Seeking a Cure
• RECRUITINGPHASE2NCT06286709
  FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis
  University of Birmingham
• RECRUITINGEARLY PHASE1NCT06197308
  Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC
  University of Minnesota

See all trials for Primary sclerosing cholangitis →